NuVasive shares ‘cheap’ with 2019 looking brighter than Q4, says Piper Jaffray

Piper Jaffray analyst Matt O’Brien said he understand concerns about NuVasive’s $6M Q4 revenue miss versus consensus, but he believes based on his view of the company’s “innovative products” and year-end checks indicating that the spine market is improving that the company should see “a beat-and-raise dynamic” next year. NuVasive is “still a great earnings power story” and the shares looks “very cheap” on an EV/EBITDA basis, said O’Brien, who keeps an Overweight rating on the stock with a price target of $70.

https://thefly.com/landingPageNews.php?id=2844843